Payment overview · 2025
General Payments
$652.97
27 reported records · 7 companies
Healthcare provider profile · identity verified
Antonio Serru Paez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAS VEGAS, NV · NPI 1407971732
Verified facts
What the public records show
CMS Open Payments records show Antonio Serru Paez, MD received $652.97 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $262.67 | 40.2% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $140.77 | 21.6% | 7 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $105.08 | 16.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.73 | 11.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.04 | 4.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.64 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.04 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $567.97 | 25 |
| Education | $85.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $140.77 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.11 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $105.08 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $98.74 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $76.36 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $64.41 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $44.82 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 93 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 71 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 161 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
161 | 64 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1064 | 375 |
| Metformin Hcl | Metformin Hcl | 606 | 220 |
| Amlodipine Besylate | Amlodipine Besylate | 600 | 203 |
| Lisinopril | Lisinopril | 520 | 170 |
| Fluticasone Propionate | Fluticasone Propionate | 370 | 123 |
| Gabapentin | Gabapentin | 367 | 143 |
| Trazodone Hcl | Trazodone Hcl | 344 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 340 | 108 |
| Losartan Potassium | Losartan Potassium | 327 | 117 |
| Omeprazole | Omeprazole | 290 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 278 | 84 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 272 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 79 |
| Carvedilol | Carvedilol | 196 | 63 |
| Naproxen | Naproxen | 193 | 103 |
| Famotidine | Famotidine | 192 | 71 |
| Buspirone Hcl | Buspirone Hcl | 183 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 58 |
| Alendronate Sodium | Alendronate Sodium | 164 | 53 |
| Linzess | Linaclotide | 161 | 64 |
| Ezetimibe | Ezetimibe | 152 | 53 |
| Diclofenac Sodium | Diclofenac Sodium | 146 | 59 |
| Furosemide | Furosemide | 130 | 47 |
| Potassium Chloride | Potassium Chloride | 129 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 43 |
| Montelukast Sodium | Montelukast Sodium | 124 | 43 |
| Donepezil Hcl | Donepezil Hcl | 108 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 41 |
| Farxiga | Dapagliflozin Propanediol | 99 | 36 |
| Methocarbamol | Methocarbamol | 96 | 51 |
| Ibuprofen | Ibuprofen | 95 | 38 |
| Eliquis | Apixaban | 93 | 38 |
| Ozempic | Semaglutide | 92 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 89 | 23 |
| Prednisone | Prednisone | 88 | 73 |
| Ventolin Hfa | Albuterol Sulfate | 83 | 21 |
| Azithromycin | Azithromycin | 82 | 72 |
| Mounjaro | Tirzepatide | 81 | 17 |
| Simvastatin | Simvastatin | 80 | 27 |
| Memantine Hcl | Memantine Hcl | 79 | 20 |
| Glipizide | Glipizide | 72 | 28 |
| Jardiance | Empagliflozin | 71 | 25 |
| Atenolol | Atenolol | 68 | 25 |
| Meclizine Hcl | Meclizine Hcl | 67 | 44 |
| Celecoxib | Celecoxib | 65 | 24 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 64 | 22 |
| Clonidine Hcl | Clonidine Hcl | 62 | 22 |
| Allopurinol | Allopurinol | 60 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 19 |
| Meloxicam | Meloxicam | 60 | 22 |
| Sertraline Hcl | Sertraline Hcl | 58 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 22 |
| Nifedipine Er | Nifedipine | 57 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 56 | 46 |
| Baclofen | Baclofen | 55 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 34 |
| Finasteride | Finasteride | 50 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 13 |
| Hydrocortisone | Hydrocortisone | 48 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 16 |
| Ketoconazole | Ketoconazole | 44 | 17 |
| Lovastatin | Lovastatin | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 31 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | suppressed |
| Tradjenta | Linagliptin | 40 | 15 |
| Vascepa | Icosapent Ethyl | 40 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 33 |
| Metronidazole | Metronidazole | 39 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | 11 |
| Januvia | Sitagliptin Phosphate | 36 | 13 |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 35 | 13 |
| Acyclovir | Acyclovir | 34 | suppressed |
| Lidocaine | Lidocaine | 34 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Xarelto | Rivaroxaban | 34 | 12 |
| Premarin | Estrogens, Conjugated | 33 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Folic Acid | Folic Acid | 31 | 12 |
| Spironolactone | Spironolactone | 31 | 11 |
| Sucralfate | Sucralfate | 31 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 13 |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | 14 |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | 11 |
| Colchicine | Colchicine | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Captopril | Captopril | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Torsemide | Torsemide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $652.97 · 27 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, BREZTRI, CREON, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, KISUNLA, LINZESS, NURTEC ODT, UBRELVY, VOQUEZNA, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error